Filter by year
-
november302018
Zambon announces approval and ARTG listing of safinamide in Australia for treatment of patients with Parkinson’s disease
-
october312018
Newron Pharmaceuticals hosts its 2018 R&D Day in New York City
-
october302018
Investment Plan for Europe: EIB backs Italian CNS drug developer Newron Pharmaceuticals with up to EUR 40m
-
october232018
Meiji Seika and Eisai announce submission of manufacturing and marketing approval application in Japan for safinamide in Parkinson’s disease
-
october152018
Newron Pharmaceuticals Announces Prominent Medical Experts to Present at its 2018 R&D Day on October 31 in New York
-
october82018
Newron Dedicates Efforts to Research and Advocacy During Rett Awareness Month in October
-
september252018
Newron Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference in New York
-
september132018
Newron reports half-year 2018 results
-
september122018
Newron Pharmaceuticals will host its 2018 R&D Day on October 31 in New York City
-
august12018
Newron Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
-
june132018
Newron provides update on STARS clinical study with sarizotan for the treatment of Rett syndrome
-
may292018
Newron Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference
-
may152018
Newron Pharmaceuticals to Present at the UBS Global Healthcare Conference 2018
-
march272018
Shareholders accepted all motions at the AGM 2018
-
march12018
Newron announces 2017 financial results and provides outlook for 2018
-
february132018
Newron Supports Global Rare Disease Day® 2018 and Rett Syndrome Studies
-
february82018
Change in the Board of Directors
-
february12018
Primary endpoint met in phase II/III clinical study of investigational Parkinson’s disease treatment safinamide in Japan